ECSP19046865A - Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico - Google Patents
Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónicoInfo
- Publication number
- ECSP19046865A ECSP19046865A ECSENADI201946865A ECDI201946865A ECSP19046865A EC SP19046865 A ECSP19046865 A EC SP19046865A EC SENADI201946865 A ECSENADI201946865 A EC SENADI201946865A EC DI201946865 A ECDI201946865 A EC DI201946865A EC SP19046865 A ECSP19046865 A EC SP19046865A
- Authority
- EC
- Ecuador
- Prior art keywords
- glp
- receptor agonist
- glucagon receptor
- hyaluronic acid
- connector
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un conjugado, o una de sus sales farmacéuticamente aceptables, que comprende un agonista del receptor de GLP-1/glucagón, un conector y un hidrogel de ácido hialurónico que porta grupos -L1-L2-L-Y-R20 , en donde Y representa un resto agonista del receptor de GLP-1/glucagón; y -L es un resto conector de fórmula (Ia), en donde la línea discontinua indica la unión a uno de los grupos amino del agonista del receptor de GLP-1/glucagón a través de la formación de un enlace amida. La invención se refiere además a composiciones farmacéuticas que comprenden dicho conjugado, así como a su uso como medicamente para tratar o prevenir enfermedades o trastornos que pueden ser tratados mediante un agonista del receptor de GLP-1/glucagón. (ver documento de imágenes).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16306613 | 2016-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP19046865A true ECSP19046865A (es) | 2019-07-31 |
Family
ID=57542941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI201946865A ECSP19046865A (es) | 2016-12-02 | 2019-07-01 | Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico |
Country Status (23)
Country | Link |
---|---|
US (2) | US10792367B2 (es) |
EP (1) | EP3548090A1 (es) |
JP (1) | JP2020503278A (es) |
KR (1) | KR20190091482A (es) |
CN (1) | CN110022902A (es) |
AR (1) | AR110299A1 (es) |
AU (1) | AU2017369723A1 (es) |
BR (1) | BR112019011139A8 (es) |
CA (1) | CA3045483A1 (es) |
CL (1) | CL2019001466A1 (es) |
CO (1) | CO2019006912A2 (es) |
CR (1) | CR20190312A (es) |
DO (1) | DOP2019000038A (es) |
EA (1) | EA201991316A1 (es) |
EC (1) | ECSP19046865A (es) |
IL (1) | IL266973A (es) |
MA (1) | MA46996A (es) |
MX (1) | MX2019006432A (es) |
PE (1) | PE20191472A1 (es) |
PH (1) | PH12019501215A1 (es) |
TW (1) | TW201832783A (es) |
UY (1) | UY37505A (es) |
WO (1) | WO2018100174A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
KR102331820B1 (ko) | 2016-03-01 | 2021-11-29 | 아센디스 파마 본 디지즈 에이/에스 | Pth 프로드럭 |
SG11201901576QA (en) | 2016-09-29 | 2019-03-28 | Ascendis Pharma Bone Diseases As | Dosage regimen for a controlled-release pth compound |
KR102611820B1 (ko) | 2016-09-29 | 2023-12-07 | 아센디스 파마 본 디지즈 에이/에스 | 낮은 피크 대 트로프 비를 가진 pth 화합물 |
TW201832783A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 包含glp-1/胰高血糖素雙重激動劑、連接子和透明質酸的接合物 |
KR20200007776A (ko) | 2017-03-22 | 2020-01-22 | 제넨테크, 인크. | 히드로겔 가교된 히알루론산 전구약물 조성물 및 방법 |
ES2953631T3 (es) | 2017-08-09 | 2023-11-14 | Sanofi Sa | Agonistas del receptor de GLP-1/glucagón en el tratamiento de la enfermedad de la esteatosis hepática y la esteatohepatitis |
UY38249A (es) | 2018-05-30 | 2019-12-31 | Sanofi Sa | Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico |
FR3084586B1 (fr) * | 2018-08-03 | 2020-11-06 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes |
WO2021214220A1 (en) | 2020-04-24 | 2021-10-28 | Boehringer Ingelheim International Gmbh | Glucagon analogues as long-acting glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis |
KR102225971B1 (ko) * | 2020-05-19 | 2021-03-10 | 주식회사 차메디텍 | 펩타이드 가교제를 이용한 히알루론산 기반의 하이드로겔 및 이의 제조 방법 |
AU2022320922A1 (en) | 2021-07-30 | 2024-01-18 | Boehringer Ingelheim International Gmbh | Dose regimen for long-acting glp1/glucagon receptor agonists |
CN114470170B (zh) * | 2022-02-22 | 2023-09-19 | 广州新济药业科技有限公司 | 一种司美格鲁肽可溶性微针组合物及其制备方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0418309B8 (pt) * | 2003-12-30 | 2021-05-25 | Genzyme Corp | "géis coesos de hialuronado e/ou hilano reticulados, processo para a preparação dos mesmos, bem como composições e dispositivos compreendendo os referidos géis". |
JP5060131B2 (ja) * | 2004-09-07 | 2012-10-31 | 中外製薬株式会社 | 水溶性ヒアルロン酸修飾物の製造方法 |
ES2458991T3 (es) | 2004-11-12 | 2014-05-07 | Novo Nordisk A/S | Formulaciones estables de péptidos insulinotrópicos |
PT1817347T (pt) * | 2004-11-24 | 2017-07-21 | Albumedix As | Resumo |
AU2006258841B2 (en) | 2005-06-13 | 2012-05-03 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
EP2570133B1 (en) | 2005-11-07 | 2016-03-23 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
KR20150116465A (ko) | 2007-02-15 | 2015-10-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-항진물질 |
US9353170B2 (en) | 2007-06-08 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Long-acting transient polymer conjugates of exendin |
ATE520714T1 (de) | 2007-06-15 | 2011-09-15 | Zealand Pharma As | Glucagonanaloga |
WO2009058662A2 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
CN101980725B (zh) | 2008-02-01 | 2013-06-12 | 阿森迪斯药物股份有限公司 | 包含可自裂解的连接体的前药 |
BRPI0911780B1 (pt) | 2008-04-29 | 2021-10-05 | Ascendis Pharma Endocrinology Division A/S | Composição farmacêutica compreendendo compostos peguilados de hormônio de crescimento humano recombinante, e profármaco |
JP5775450B2 (ja) | 2008-06-17 | 2015-09-09 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | グルカゴン/glp−1受容体コアゴニスト |
PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
NZ593813A (en) | 2008-12-15 | 2013-02-22 | Zealand Pharma As | Glucagon analogues |
ES2439499T3 (es) | 2008-12-15 | 2014-01-23 | Zealand Pharma A/S | Análogos de glucagón |
CN102282167B (zh) | 2008-12-15 | 2014-08-13 | 西兰制药公司 | 胰高血糖素类似物 |
CA2747112A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
NZ597981A (en) | 2009-07-13 | 2014-02-28 | Zealand Pharma As | Acylated glucagon analogues |
KR20120089843A (ko) | 2009-07-31 | 2012-08-14 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린 링커 접합체를 포함한 프로드럭 |
FR2952695B1 (fr) | 2009-11-13 | 2012-03-30 | Commissariat Energie Atomique | Reservoir de stockage d'hydrogene a hydrures metalliques |
PT2498801T (pt) | 2009-11-13 | 2018-05-02 | Sanofi Aventis Deutschland | Composição farmacêutica compreendendo despro36exendin-4(1-39)-lys6-nh2 e metionina |
US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
AR079345A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
CA2792663A1 (en) | 2010-03-26 | 2011-09-29 | Novo Nordisk A/S | Novel glucagon analogues |
EA023925B1 (ru) | 2010-04-27 | 2016-07-29 | Зилэнд Фарма А/С | Пептидные конъюгаты агонистов рецептора glp-1 и их применение |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
CN102918177B (zh) | 2010-05-31 | 2015-09-09 | 株式会社捷太格特 | 覆盖部件的制造方法 |
EP2579435B1 (en) | 2010-06-01 | 2016-11-30 | Honda Motor Co., Ltd. | Controller for dc/dc converter |
AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
MY164680A (en) | 2011-06-17 | 2018-01-30 | Hanmi Science Co Ltd | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
US20150316188A1 (en) | 2012-06-29 | 2015-11-05 | University Of South Australia | Fluid connection ports |
UA116217C2 (uk) * | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
ES2653765T3 (es) | 2012-12-21 | 2018-02-08 | Sanofi | Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón |
AU2014345570B2 (en) | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
TW201609798A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Exendin-4胜肽類似物 |
EP3080155A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
US10188759B2 (en) * | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
AR105319A1 (es) * | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201832783A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 包含glp-1/胰高血糖素雙重激動劑、連接子和透明質酸的接合物 |
-
2017
- 2017-11-30 TW TW106141763A patent/TW201832783A/zh unknown
- 2017-11-30 AR ARP170103361A patent/AR110299A1/es unknown
- 2017-12-01 EA EA201991316A patent/EA201991316A1/ru unknown
- 2017-12-01 US US15/829,596 patent/US10792367B2/en active Active
- 2017-12-01 EP EP17822168.5A patent/EP3548090A1/en active Pending
- 2017-12-01 WO PCT/EP2017/081217 patent/WO2018100174A1/en unknown
- 2017-12-01 CA CA3045483A patent/CA3045483A1/en not_active Abandoned
- 2017-12-01 MX MX2019006432A patent/MX2019006432A/es unknown
- 2017-12-01 PE PE2019001081A patent/PE20191472A1/es unknown
- 2017-12-01 AU AU2017369723A patent/AU2017369723A1/en not_active Abandoned
- 2017-12-01 KR KR1020197018576A patent/KR20190091482A/ko active Search and Examination
- 2017-12-01 BR BR112019011139A patent/BR112019011139A8/pt not_active IP Right Cessation
- 2017-12-01 MA MA046996A patent/MA46996A/fr unknown
- 2017-12-01 CN CN201780074647.0A patent/CN110022902A/zh active Pending
- 2017-12-01 JP JP2019529643A patent/JP2020503278A/ja not_active Abandoned
- 2017-12-01 CR CR20190312A patent/CR20190312A/es unknown
- 2017-12-01 UY UY0001037505A patent/UY37505A/es not_active Application Discontinuation
-
2019
- 2019-02-21 DO DO2019000038A patent/DOP2019000038A/es unknown
- 2019-05-29 IL IL266973A patent/IL266973A/en unknown
- 2019-05-30 CL CL2019001466A patent/CL2019001466A1/es unknown
- 2019-05-31 PH PH12019501215A patent/PH12019501215A1/en unknown
- 2019-06-27 CO CONC2019/0006912A patent/CO2019006912A2/es unknown
- 2019-07-01 EC ECSENADI201946865A patent/ECSP19046865A/es unknown
- 2019-10-28 US US16/665,785 patent/US11141489B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2019006432A (es) | 2019-08-21 |
US10792367B2 (en) | 2020-10-06 |
AU2017369723A1 (en) | 2019-07-18 |
TW201832783A (zh) | 2018-09-16 |
CR20190312A (es) | 2019-09-11 |
CN110022902A (zh) | 2019-07-16 |
AR110299A1 (es) | 2019-03-13 |
CO2019006912A2 (es) | 2020-04-24 |
CA3045483A1 (en) | 2018-06-07 |
EA201991316A1 (ru) | 2019-10-31 |
JP2020503278A (ja) | 2020-01-30 |
MA46996A (fr) | 2019-10-09 |
PH12019501215A1 (en) | 2019-08-19 |
PE20191472A1 (es) | 2019-10-16 |
US20180154005A1 (en) | 2018-06-07 |
BR112019011139A8 (pt) | 2020-03-24 |
BR112019011139A2 (pt) | 2019-10-01 |
UY37505A (es) | 2018-06-29 |
KR20190091482A (ko) | 2019-08-06 |
IL266973A (en) | 2019-07-31 |
CL2019001466A1 (es) | 2019-10-11 |
WO2018100174A1 (en) | 2018-06-07 |
DOP2019000038A (es) | 2019-05-31 |
EP3548090A1 (en) | 2019-10-09 |
US20200155688A1 (en) | 2020-05-21 |
US11141489B2 (en) | 2021-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP19046865A (es) | Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico | |
AR105319A1 (es) | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico | |
CO6690765A2 (es) | Profármacos que comprenden un conjugado de conector de exendina | |
NI201200012A (es) | Profármacos que comprenden un conjugado de insulina - conector | |
CL2016001809A1 (es) | Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x (divisional sol. n° 3344-15). | |
CL2017000379A1 (es) | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7) | |
UA114710C2 (uk) | Похідне оксинтомодуліну та фармацевтична композиція для запобігання або лікування ожиріння, яка його містить | |
BR112017001010A2 (pt) | inibidores peptídicos orais do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias intestinais | |
MX2019012676A (es) | Derivados de 2-aminoquinolina. | |
AR099975A1 (es) | Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón | |
CL2012000092A1 (es) | Compuestos derivados de piridina y pirazina o una sal de los mismos, moduladores de proteina quinasa cdk9; composicion farmaceutica que los comprende, util para el tratamiento del cancer, hipotrofia cardiaca, vih y enfermedades inflamatorias. | |
MX369818B (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
ECSP13012871A (es) | Moduladores del receptor de glucagón | |
UY30572A1 (es) | N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 | |
AR100935A1 (es) | CONJUGADOS DE FÁRMACO-ANTICUERPO ANTI-RECEPTOR DE FOLATO a (FRA) Y MÉTODOS DE USO DE LOS MISMOS | |
CL2012001352A1 (es) | Compuestos heterocíclicos derivados de amina, moduladores del receptor s1p; composición farmacéutica que los comprende; uso para tratar enfermedades oculares, vasculares sistémicas inflamatorias, autoinmunitarias e inmunosupresión, cicatrización y dolor entre otras. | |
MX2020003732A (es) | Derivado de anillo fusionado como inhibidor del receptor a2a. | |
CL2019001991A1 (es) | Moduladores del receptor de estrógeno. | |
CL2017001720A1 (es) | Nuevos derivados de bencimidazol como agentes antihistamínicos. | |
UY35209A (es) | Compuestos tricíclicos | |
UY33824A (es) | ?moduladores del receptor del glucagón?. | |
CL2010001432A1 (es) | Compuestos derivados de 2-oxo-alquil-1-piperazin-2-ona, afines por los receptores p75ntr; procedimiento para preparar los compuestos; compuesto intermediario; medicamento y composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos utiles para tratar enfermedades neurodegenerativas. | |
ECSP16094286A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas | |
UY38249A (es) | Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico | |
ECSP12011632A (es) | Profármacos que comprenden un conjugado de insulina-conector |